Paradigm Biopharmaceuticals Ltd. · ASX:PAR
Paradigm Biopharmaceuticals — Shareholder Meeting (November 2025)
26 slides from Paradigm Biopharmaceuticals's shareholder meeting presentation, Nov 19, 2025
Slide 1: 2025 Annual General Meeting Chairman's Address
ASX RELEASE 19 November 2025 2025 Annual General Meeting Chairman’s Address Dear Shareholders, As Chair and Managing Director, I am pleased to report on the strong progress Paradigm Biopharmaceuticals has delivered over the past 12 months. 2025 has been a year defined by operational execution, disci
Slide 2: Chairman's Address (continued)
placement at $0.40 per share, enabling accelerated site activation and manufacturing readiness. In July 2025, we supplemented this with a US$27 million (approximately A$41 million) convertible note facility with Obsidian Global Partners, secured following a competitive international process. The Obs
Slide 3: Thank you / About Paradigm Biopharmaceuticals
Thank you. Paul Rennie Chair and Managing Director Paradigm Biopharmaceuticals Ltd About Paradigm Biopharmaceuticals Paradigm Biopharmaceuticals Ltd. (ASX: PAR) is a late-stage drug development company driven by a purpose to improve patients’ health and quality of life by discovering, developing, an
Slide 4: Annual General Meeting | Nov 2025
For personal use only ANNUAL GENERAL MEETING | 19 NOV 2025
Slide 5: Board of Directors
Paradigm Biopharma NOV 2025 2 BOARD OF DIRECTORS Experienced team to drive clinical success and commercialisation For personal use only MATTHEW FRY AMOS MELTZER Non-Executive Director PAUL RENNIE Non-Executive Director Chair & Managing Director
Slide 6: Login and meeting registration
Paradigm Biopharma NOV 2025 3 LOGIN & For personal use only Go to https://investor.auomic.com.au/#/home Under Meeting menu, click on “Join Meeting” For Support call: 1300 816 159 (within Australia) +61 2 8072 1479 (overseas) Follow the prompts to register your relevant holding(s)
Slide 7: How to Ask a Question
Paradigm Biopharma 02/12/21 Nov 2025 44 How to Ask a Question For personal use only
Slide 8: Agenda
Paradigm Biopharma NOV 2025 5 COMPANY UPDATE For personal use only Agenda 01 Company Update Notice of meeting & 02 formal business PAUL RENNIE, Questions relating to Managing 03 Company Update Director
Slide 9: Disclaimer
Paradigm Biopharma NOV 2025 6 DISCLAIMER This document, together with any information communicated by Paradigm Biopharmaceuticals Ltd ASX:PAR (known as “Paradigm”, “Paradigm For personal use only Biopharma” or “the Company”), in any presentation or discussion relating to this document (collectively,
Slide 10: Company Overview
Paradigm Biopharma NOV 2025 7 COMPANY OVERVIEW Paradigm is advancing pentosan polysulfate sodium (PPS) as a novel, non-opioid therapy to transform the treatment of osteoarthritis. By For personal use only targeting the underlying inflammation and structural degeneration that drive disease progressio
Slide 11: Company Achievements 2025 YTD
Paradigm Biopharma NOV 2025 8 COMPANY ACHIEVEMENTS 2025 YTD For personal use only Phase 3 trial transitioned from setup to active dosing across AUS & US. Advanced Clinical appointed as Acquisition of Proteobioactives global CRO with NBCD engaged in → broadened OA pipeline. a complementary role, broa
Slide 12: Osteoarthritis By Numbers
Paradigm Biopharma NOV 2025 9 Osteoarthritis People affected by OA Globally1 Moderate – to – Severe OA3 For personal use only By Numbers Zilosul® is a non-opioid subcutaneous 528m+ 65 % of all OA injectable aimed to treat OA patients dissatisfied with current Knee OA most prevalent2 treatments4: pai
Slide 13: Unmet Need
Paradigm Biopharma NOV 2025 10 UNMET NEED For personal use only Limited treatment High economic Strong demand for options: burden: alternatives: Current treatments (NSAIDs, OA costs the US healthcare A safe, effective treatment steroids, HA) focus on short- system over $136B with long-term benefits
Slide 14: Unmet Need: Current Treatment Options
Paradigm Biopharma NOV 2025 11 UNMET NEED Invasive For personal use only Effective Non-validated Ineffective Analgesics,NSAIDS • Daily use • GI, CV risk with prolonged use. Opioids • Severe side-effects • Addictive *Royal Australian College of General Practitioners hold a ‘strong against’ recommenda
Slide 15: Addressing Full OA Spectrum
Paradigm Biopharma NOV 2025 12 ADDRESSING FULL OA SPECTRUM For personal use only 01. 02. 03. Dual PPS-based therapies Together, they aim to shift Aligned with FDA focus on transforming osteoarthritis treatment earlier, reduce non-opioid chronic pain management across the full opioid reliance, and im
Slide 16: Addressing Full OA Spectrum: Under Investigation
Paradigm Biopharma NOV 2025 13 ADDRESSING FULL OA SPECTRUM Under investigation For personal use only • Pentacoxib™ (oral PPS + COX-2) – safe, non-opioid option for mild-to- moderate OA. • Applications across vetinary and human OA • Zilosul® (injectable PPS) Phase 3 program for moderate-to-severe OA
Slide 17: Phase 3 OA
Paradigm Biopharma NOV 2025 14 For personal use only PHASE 3 OA
Slide 18: PARA_OA_012 Phase 3 Program Overview
Paradigm Biopharma Nov 2025 1515 02/12/21 PARA_OA_012 PHASE 3 PROGRAM OVERVIEW Global Pivotal Phase 3 Trial Progressing Toward Mid-2026 Interim Analysis For personal use only 01 02 03 04 05 Study design Dosing regimen Primary endpoint Trial oversight Interim analysis 466-patient, randomised, 2 mg/kg
Slide 19: PARA_OA_012 Phase 3 Site Locations by State
Paradigm Biopharma Nov 2025 1616 02/12/21 PARA_OA_012 Phase 3 Site Locations by State For personal use only United States Australia 45 sites 11 sites
Slide 20: Lead Program Osteoarthritis: Phase 3 Achievements
Paradigm Biopharma Nov 2025 1717 02/12/21 LEAD PROGRAM OSTEOARTHRITIS Phase 3 Achievements For personal use only Site Activations Enrollment Addition of NBCD as Complimentary CRO • 60 sites across Australia, US, • Hundreds in screening with • NBCD engaged alongside Hong Kong and Moldova on track str
Slide 21: Company Update
Paradigm Biopharma NOV 2025 1818 For personal use only 02/12/21 C o m p a n y UPDATE
Slide 22: Finance: Strong Capital Position to Deliver Key Milestones
Paradigm Biopharma Nov 2025 1919 02/12/21 FINANCE Strong Capital Position to Deliver Key Milestones For personal use only Obsidian Facility 01 02 03 Key focus has been to secure Each conversion to date under The most recent US$5 million flexible sources of capital while the US$27 million Obsidian dr
Slide 23: Finance: Runway and Funding Outlook
Paradigm Biopharma Nov 2025 2020 02/12/21 FINANCE Runway and Funding Outlook For personal use only R&D investment averaging Forecast cash outflows for Q4 Fully funded through to the A$5–6 million per quarter as CY25 of A$13–15 million, mid-2026 interim analysis of global site activation and reflecti
Slide 24: Outlook
Paradigm Biopharma Nov 2025 2121 02/12/21 OUTLOOK For personal use only Recruitment Completion (1H Interim Analysis (Mid-2026) 2026) Key efficacy and safety readout Global enrolment completion to guide next regulatory and with strong retention and commercial steps. adherence. Regulatory Engagement C
Slide 25: News Flow & Catalysts: Upcoming Catalysts
Paradigm Biopharma Nov 2025 2222 02/12/21 NEWS FLOW & CATALYSTS For personal use only Upcoming Catalysts Event Target Date PARA_OA_012 – 25% & 50% Recruitment of participants 2H 2025* Regional licensing agreement(s) in OA Ongoing End of PARA_OA_008 – Phase 2 clinical trial data manuscripts peer revi
Slide 26: Thank You For Your Attendance
Paradigm Biopharma NOV 2025 23 For personal use only THANK YOU FOR YOUR ATTENDANCE For more information please visit: https://investors.paradigmbiopharma.com
Paradigm Biopharmaceuticals — Shareholder Meeting (November 2025) on 6ix